Results 241 to 250 of about 27,891 (313)

Semaglutide impacts skeletal muscle to a similar extent as caloric restriction in mice with diet‐induced obesity

The Journal of Physiology, EarlyView.
Abstract figure legend Four weeks of semaglutide treatment causes significant reductions in total body weight, fat mass, lean mass, and grip strength in mice with diet induced obesity. Mice treated with semaglutide lost a greater amount of total body weight and fat mass compared to mice fed fed a calorie matched diet.
S. Jeromson, B. Baranowski, M. Akcan, B. D. Waters, K. Eisner, A. Bellucci, S. Trang, A. Abolhassani, M. A. Tello‐Palencia, A. Schweitzer, B. Stefanska, C. J. Mitchell, David C. Wright   +12 more
wiley   +1 more source

Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. [PDF]

Pharmaceuticals (Basel)
Hindi A, Mekkawy M, Shokr H.
europepmc   +1 more source

Sex‐specific metabolic responses to glucagon receptor agonism and modulation of the FGF21‐glucagon axis in female mice

The Journal of Physiology, EarlyView.
Abstract figure legend Therapies targeting the glucagon receptor are being explored for obesity treatment, yet most preclinical studies remain male biased. In this study, Merrild and Johansen et al. show that in diet‐induced obese wild‐type mice a long‐acting glucagon analogue (LA‐Gcg) elicits sexually dimorphic effects on weight loss, food intake ...
Christoffer Merrild, Valdemar Brimnes Ingemann Johansen, Christoffer Clemmensen, Pablo Ranea‐Robles   +3 more
wiley   +1 more source

Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis. [PDF]

Front Endocrinol (Lausanne)
Zhu X, Wang X, Zhang P, Yang Z, Zhao N, Li J, Shi Y, Zhao Y, Ma J.   +8 more
europepmc   +1 more source

Effects of GLP-1 Receptor Agonists on Muscle Mass, Strength, and Quality in MASLD: A Systematic Review. [PDF]

Liver Int
Iorra F, Jayakar T, Yee M, Thursz MR, Schaan BD, Manousou P.   +5 more
europepmc   +1 more source

Real-world effectiveness, safety, and quality of life of biosynthetic semaglutide in Pakistani adults with type 2 diabetes mellitus: a study protocol. [PDF]

J Pharm Policy Pract
Daoud Butt M, Hussain A, Ong SC.
europepmc   +1 more source

The Economic Burden of Metabolic Dysfunction‐Associated Steatohepatitis (MASH) With Cirrhosis: A Systematic Review

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Background & Aims The clinical burden of metabolic dysfunction‐associated steatohepatitis (MASH) is substantial and there are no approved treatments for patients with cirrhosis. This systematic review aimed to better understand the economic burden in this population.
Jeffrey V. Lazarus, Caroline Freeman, Hannes Hagström, Mazen Noureddin, Riku Ota, Mary E. Rinella, Giada Sebastiani, Fotis Tefos, Zobair M. Younossi   +8 more
wiley   +1 more source

GLP-1 receptor agonists for weight loss: A systematic review and meta-analysis of randomized controlled trials. [PDF]

Medicine (Baltimore)
Ahmad N, Alruwayyes A, Alarjani A, Tawhari A, Aldosri A, Alahmari A, Balaha M.   +6 more
europepmc   +1 more source

Examining HbA1c in Frail Older Adults: A Linked Data Cohort Study

Australasian Journal on Ageing, Volume 45, Issue 2, June 2026.
ABSTRACT Objective Diabetes and frailty pose a significant issue for society. Previous research has shown a mixed relationship between diabetes and frailty in older people, indicating a complex interrelationship. The aim of this study was to examine the association between routinely collected HbA1c testing data and frailty in a large cohort from ...
Gideon Meyerowitz‐Katz, Julee McDonagh, Scott William, Reejamol John, Tien‐Ming Hng, Mark McLean, Mary Bul, Richard I. Lindley, Caleb Ferguson   +8 more
wiley   +1 more source